Cancer remains a leading cause of global mortality, with increasing incidence and limited therapeutic options for advanced-stage disease. Accumulating evidence indicates that mitochondrial reprogramming is a key regulator of cancer biology, coordinating energy metabolism, oxidative stress, epigenetic remodeling, and...
K. Liu, Xin-Yue Cui, Li-Min Gan et al.· Cell Communication and Signa...· 0 citations
Immune checkpoint inhibitors (ICIs) have reshaped systemic therapy for hepatocellular carcinoma (HCC), but durable benefit remains limited to a subset of patients because of tumor-intrinsic and microenvironmental mechanisms of immune resistance. Canonical epigenetic and epitranscriptomic alterations, including DNA meth...
Ya-Fei Zhi, Yan Guo, Hui-Fang Wei et al.· Clinical and Molecular Hepat...· 0 citations
An RNMT-ADRB2-MYCBP-PPP axis that integrates epitranscriptomic regulation with adrenergic signaling to promote metabolic reprogramming and malignant progression in ESCC is defined.
Zi-Han Zhang, Fei-Fei Liu, Peng Wang et al.· Cancer Research· 0 citations
The SF3b complex is positioned as a disease-modifying hub at the intersection of RNA splicing and cancer biology, and highlights the opportunities and challenges associated with therapeutically targeting spliceosome components in oncology.
Shulin Li, Li-Tong Shang, Jia-Yi Yang et al.· Blood Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
